Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and PK of SP2086 in Healthy Volunteers
NCT02821871Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 at Day 12, Maximum Plasma Concentration of SP2086 Acid at Day 12 and 4 more. Status: unknown.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02821871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821871.